Skip to main content

Table 2 Patient characteristics according to TDT (< 400 and ≥ 400) in pathological stages IA1, IA2, IA3 and IB (n = 176)

From: Solid component tumor doubling time is a prognostic factor in non-small cell lung cancer patients

  Stage IA1
(n = 49)
Stage IA2 (n = 61) Stage IA3 (n = 20) Stage IB
(n = 46)
  TDT < 400 TDT ≥ 400   TDT < 400 TDT ≥ 400   TDT < 400 TDT ≥ 400   TDT < 400 TDT ≥ 400  
  n = 17 n = 32 p-value n = 34 n = 27 p-value n = 13 n = 7 p-value n = 31 n = 15 p-value
Age (mean ± SD) 73.9 ± 7.8 68.1 ± 8.3 0.02 69.4 ± 10.9 66.5 ± 10.1 0.299 75.4 ± 5.2 63.3 ± 11.1 0.03 72.3 ± 7.6 72.5 ± 9.6 0.966
Sex (Male/Female) 6 (35.3%)/11 (64.7%) 11 (34.4%)/21 (65.6%) 0.949 26 (76.5%)/8 (23.5%) 13 (48.1%)/14 (51.9%) 0.022 10 (76.9%)/3 (23.1%) 4 (57.1%)/3 (42.9%) 0.357 24 (77.4%)/7 (22.6%) 11 (73.3%)/4 (26.7%) 0.761
Smoking History (Never/Ever) 5 (29.4%)/12 (70.6%) 8 (25%)/24 (75%) 0.739 22 (64.7%)/12 (35.3%) 11 (40.7%)/16 (59.3%) 0.062 10 (76.9%)/3 (23.1%) 4 (57.1%)/3 (42.9%) 0.357 26 (83.9%)/5 (16.1%) 10 (66.7%)/5 (33.3%) 0.257
Serum CEA (mean ± SD) 2.2 ± 1.1 2.8 ± 3.1 0.488 2.6 ± 1.8 3.2 ± 1.7 0.223 10.7 ± 24.4 2.8 ± 1.1 0.408 4.2 ± 3.0 9.3 ± 20.0 0.172
Type of resection
 Segmentectomy 6 (35.3%) 8 (25%) 0.448 5 (14.7%) 3 (11.1%) 0.68 0 0 0 1 (6.7%) 0.326
 Lobectomy 11 (64.7%) 24 (75%)   29 (85.3%) 24 (88.9%)   13 (100%) 7 (100%)   31 (100%) 14 (93.3%)  
 Pneumonectomy 0 0   0 0   0 0   0 0  
Histological type
 Adenocarcinoma 16 (94.1%) 31 (96.9%) 0.578 21 (61.8%) 25 (92.6%) 0.021 7 (53.8%) 6 (85.7%) 0.319 18 (58.1%) 10 (66.7%) 0.802
 Squamous cell carcinoma 1 (5.9%) 0   7 (20.6%) 1 (3.7%)   4 (30.7%) 1 (14.3%)   9 (29%) 3 (20%)  
 Others 0 1 (3.1%)   6 (17.6%) 1 (3.7%)   2 (15.4%) 0   4 (12.9%) 2 (13.3%)  
Solid component
 Pure solid/mixed GGO 10/7 11/22 0.084 19/15 11/16 0.24 6/7 2/5 0.44 10/21 5/10 0.94
  1. TDT Tumor Doubling Time, SD Standard deviation